Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo.

作者: DM Monroe , DM McCord , MN Huang , KA High , RL Lundblad

DOI: 10.1182/BLOOD.V73.6.1540.1540

关键词:

摘要: Factor IX Hilo is a variant factor molecule that has no detectable coagulant activity. The defect in arises from point mutation the gene such protein Arg180 converted to Gln. Activation of by Xla was monitored using fluorescent active site probe p-aminobenzamidine. Normal showed complete activation one hour as determined measuring increase fluorescence when p-aminobenzamidine bound activated IX. even after 24 hours, indicating not exposed. Polyacrylamide gel electrophoresis cleaved light chain plus larger peptide with molecular weight equivalent heavy covalently linked an peptide. Amino terminal amino acid sequencing cleavage only at Arg145-Ala146, Gln180-Val181 bond and thus presence patient plasma responsible for having very long ox brain prothrombin time characteristic severe hemophilia Bm. Patient had 100 seconds Thrombotest kit, significantly prolonged over normal control value 45 seconds. When depleted immunoaffinity column, decreased 41 added back plasma, same affinity or CRM- B patient, prolonged. We conclude Gln results cannot be Xla. Further, our data suggest interacts components extrinsic pathway give time.

参考文章(25)
R M Bertina, I K van der Linden, Factor IX Deventer-evidence for the heterogeneity of hemophilia BM. Thrombosis and Haemostasis. ,vol. 47, pp. 136- 140 ,(1982) , 10.1055/S-0038-1657148
J Ware, L Davis, D Frazier, SP Bajaj, DW Stafford, Genetic defect responsible for the dysfunctional protein: factor IXLong Beach. Blood. ,vol. 72, pp. 820- 822 ,(1988) , 10.1182/BLOOD.V72.2.820.820
Claudia M. Noyes, Optimization of complex separations in high-performance liquid chromatography Journal of Chromatography A. ,vol. 266, pp. 451- 460 ,(1983) , 10.1016/S0021-9673(01)90916-1
B. Osterud, S. I. Rapaport, Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 74, pp. 5260- 5264 ,(1977) , 10.1073/PNAS.74.12.5260
R G Di Scipio, K Kurachi, E W Davie, Activation of human factor IX (Christmas factor). Journal of Clinical Investigation. ,vol. 61, pp. 1528- 1538 ,(1978) , 10.1172/JCI109073
Akira Yoshioka, Yoshiaki Ohkubo, Takuya Nishimura, Ichiro Tanaka, Hiromu FuKui, Kanji Ogata, Tadashi Kamiya, Hoyu Takahashi, Heterogeneity of factor IX BM difference of cleavage sites by factor XIa and Ca2+in factor IX Kashihara, Factor IX Nagoya and Factor IX Niigata Thrombosis Research. ,vol. 42, pp. 595- 604 ,(1986) , 10.1016/0049-3848(86)90338-5
Cecil Hougie, JeremiahJ. Twomey, HÆMOPHILIA BM: A NEW TYPE OF FACTOR-IX DEFICIENCY The Lancet. ,vol. 289, pp. 698- 700 ,(1967) , 10.1016/S0140-6736(67)92179-4